Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Flavin derivatives

A technology for compounds and prodrugs, applied in the field of flavin derivatives, can solve the problems of not identifying the type of nuclear switch, not identifying FMN, etc.

Inactive Publication Date: 2011-09-07
BIORELIX
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, no instances of FMN, TPP, nor any other nuclear switch type have been identified in humans so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Flavin derivatives
  • Flavin derivatives
  • Flavin derivatives

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0683] The preparation method of the compound of the present invention

[0684] Compounds of formula I, II, III, IV, V and VI and salts thereof can be prepared using methods described and practiced herein and methods analogous thereto and methods well known in the chemical arts. Such methods include, but are not limited to, those described below. In the descriptions of synthetic methods described herein, it is understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiments, and workup methods, are chosen to be standard for this reaction and should be readily understood by the present author. recognized by those skilled in the art. Thus, sometimes the reaction may need to be performed at elevated temperatures or for longer or shorter periods of time. Those skilled in the art of organic synthesis understand that the functional groups present on different parts of the molecule must be compatible w...

Embodiment 1

[0734] On-line probing assays, as described by Regulski and Breaker in "In-line probing analysis of riboswitches", (2008), Methods in Molecular Biology, Vol 419, pp 53-67, the contents of which are fully incorporated by reference, were performed with To estimate the dissociation binding constants for each of the ligands described herein interacting with FMN riboswitches amplified from the Bacillus subtilis genome. By in vitro transcription from PCR-generated templates and using the method described above [5'- 32 P]-tags were used to prepare pre-mRNA leaders (Regulski and Breaker, In-line probing analysis of riboswitches (2008), Methods in Molecular Biology Vol 419, pp 53-67). Dissolve approximately 5 nM labeled RNA precursor in 20 mM MgCl at 25 °C 2 , 50 mM Tris HCl (pH 8.3, at 25° C.) in the presence or absence of increasing concentrations of the respective ligands for 41 hours. The online cleavage products were separated by 10% polyacrylamide gel electrophoresis (PAGE), an...

Embodiment 1A

[0739] MIC determinations were performed in 96-well clear round bottom culture plates in a final volume of 100 μL according to the method established by the Clinical Laboratory Standards Institute (CLSI). Briefly, test compounds suspended in 100% DMSO (or another suitable solubilization buffer) are added to aliquots of media appropriate for the indicated pathogens to a total volume of 50 [mu]L. This solution was serially diluted 2-fold into successive tubes of the same medium to obtain the test compound concentration range suitable for the assay. To each dilution of test compound in medium was added 50 [mu]l of bacterial suspension from overnight culture growth in medium appropriate for the indicated pathogen. The final bacterial inoculum was approximately 10 5 -10 6 CFU / well. After 18-24 hours of growth at 37°C, the MIC was defined as the lowest concentration of an antimicrobial detectable with the naked eye that completely inhibited the growth of the microorganism relativ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and / or anti-infectives. The invention also provides method of making novel flavin derivatives.

Description

[0001] related application [0002] This application claims priority to US Provisional Application No. US 61 / 188,619, filed August 11, 2008, and US Provisional Application No. US 61 / 211,314, filed March 25, 2009, both of which are incorporated by reference in their entirety. technical field [0003] The present invention relates to flavin derivatives, uses thereof and compositions used as riboswitch ligands and / or anti-infectives. The invention also provides a preparation method of the neoflavin derivative. Background of the invention [0004] The rapid rate of increase in antibiotic resistance over the past few decades has raised serious concerns that currently available antibiotic treatment options will soon become ineffective. Due to the widespread use of antibiotics combined with the rapid rate of increase in bacterial resistance, in stark contrast to the decades-old chemical platforms available for therapy, new drugs must be developed against bacterial pathogens. [0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A01N43/60A61K31/495A61K31/505
CPCA61K31/495A61K31/505C07D475/02A61P31/04Y02A50/30A61K31/4985A61K31/519A61K31/498
Inventor B·R·狄克逊K·F·布鲁恩特J·伯曼P·D·G·克伊施D·奥斯特曼K·哈普利特K·凯尔斯P·维肯斯J·威尔森J·吴J·明B·R·伊万斯J·A·雷比H·J·朔斯塔莱兹F·C·希尔沃利诺D·昂德伍德A·拜罗D·穆恩V·彭T·卡施S·埃沃拉N·巴布拉斯R·盖德伍德
Owner BIORELIX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com